Dare Bioscience, Inc. (DARE) Valuation — DCF, Graham & Comparables

Dare Bioscience, Inc. (DARE) — Price $0.73 HealthcareBiotechnology — NASDAQ

Latest reported results:

Valuation dashboard for Dare Bioscience, Inc. (DARE) with P/E N/A, P/B -18.96, EV/EBITDA -0.53 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.

Analysis Summary

Trailing-twelve-month margins: gross margin -89.5%, operating margin -8.1%, net margin -8.0%.

At the current price of $0.73, DARE has negative trailing earnings (P/E not meaningful) and an ROE of -7.48%. Market capitalisation stands at $11M.

Balance sheet quality for DARE: current ratio of 1.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.

Valuation Ratios

Price / Book-18.96
EV / EBITDA-0.53
Dividend Yield0.00%

Valuation Models

DCF Fair Value$0.18
vs Current Price-75.6%

Peer Comparison

SymbolCompanyMarket CapP/EP/BROE
DAREDare Bioscience, Inc.$11M-7.5%
0QZU.LVertex Pharmaceuticals Incorporated$131.8B
VRTXVertex Pharmaceuticals Incorporated$130.6B29.766.4623.3%
0R2M.LRegeneron Pharmaceuticals, Inc.$84.0B
REGNRegeneron Pharmaceuticals, Inc.$79.8B18.792.5713.8%
ARGXargenx SE$61.2B36.307.4021.7%
MRNAModerna, Inc.$57.8B1.34-39.2%
RVMDRevolution Medicines, Inc.$41.7B15.96-96.4%

Price

Price$0.73
Market Cap$11M
ExchangeNASDAQ
CountryUS

Profitability

Return on Equity-748.08%
Return on Invested Capital-179.10%
Return on Assets-49.12%
Gross Margin-89.45%
Operating Margin-813.38%
Net Margin-804.37%

Related companies: ADTX · AIMD · ANL · ASBP · ATHA · CTXR · FBLG

Explore sector: Healthcare · Biotechnology

More sections of DARE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks